[Management of adverse effects of targeted therapy toxicities in oncology].
Elodie Coquan(Centre François Baclesse), Florence Joly(Unknown), Barbara Lireux, Eric Lamy, Sixtine de Raucourt, Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Patrick Henri, Emmanuel Sevin, Corinne Delcambre(Centre François Baclesse), Radj Gervais(Centre François Baclesse), Karine Bouhier‐Leporrier(Université Paris Cité)
PubMed
January 1, 2012
Cited by 3
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer
|New England Journal of Medicine|2018|2.8k
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
|Journal of Clinical Oncology|2004|2.4k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k